Title of article
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 yearsʹ adjuvant treatment for breast cancer
Author/Authors
ATAC Trialistsʹ Group، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
3
From page
60
To page
62
Abstract
The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared w
Journal title
The Lancet
Serial Year
2005
Journal title
The Lancet
Record number
587494
Link To Document